WHAT IS CLAIMED:

1. A liquid pharmaceutical formulation comprising:
   (i) furosemide, or a pharmaceutically acceptable salt thereof;
   (ii) one or more pharmaceutically acceptable excipients, wherein the amount of the one or more pharmaceutically acceptable excipients in the liquid pharmaceutical formulation is from about 0.1 % (w/w) to about 30 % (w/w); and
   (iii) a pharmaceutically acceptable buffer,
   wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 40 mg/mL to about 250 mg/mL, and
   the one or more pharmaceutically acceptable excipients is selected from the group consisting of ethanol, benzyl alcohol, glycerin, sodium chloride, a polyethylene glycol (PEG), propylene glycol, a polysorbate, a polyvinylpyrrolidone (PVP), and any combination thereof..

2. The liquid pharmaceutical formulation of claim 1, wherein the one or more pharmaceutically acceptable excipients comprises benzyl alcohol.

3. The liquid pharmaceutical formulation of claim 1 or 2, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.1 % (w/w) to about 10 % (w/w).

4. The liquid pharmaceutical formulation of claim 1 or 2, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.5 % (w/w) to about 5 % (w/w).

5. The liquid pharmaceutical formulation of any one of claims 1-4, wherein the concentration of the pharmaceutically acceptable buffer in the liquid pharmaceutical formulation is from about 25 mM to about 500 mM.

6. The liquid pharmaceutical formulation of any one of claims 1-5, wherein the pharmaceutically acceptable buffer comprises a buffering agent selected from the group consisting of histidine, a citrate salt, sodium phosphate, potassium phosphate, tromethamine or a pharmaceutically acceptable salt thereof, and any combination thereof.

7. The liquid pharmaceutical formulation of any one of claims 1-5, wherein the buffering agent is tromethamine or a pharmaceutically acceptable salt thereof.

8. The liquid pharmaceutical formulation of claim 7, wherein the concentration of tromethamine or a pharmaceutically acceptable salt thereof in the liquid pharmaceutical

formulation is from about 25 mM to about 250 mM.

9. The liquid pharmaceutical formulation of claim 7, wherein the concentration of tromethamine or a pharmaceutically acceptable salt thereof in the liquid pharmaceutical formulation is from about 25 mM to about 150 mM.

10. The liquid pharmaceutical formulation of claim 1, comprising:
(i) furosemide, or a pharmaceutically acceptable salt thereof;
(ii) from about 0.5 % (w/w) to about 5 % (w/w) benzyl alcohol; and
(iii) from about 25 mM to about 150 mM tromethamine or a pharmaceutically acceptable salt thereof,
wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 60 mg/mL to about 120 mg/mL, and the liquid pharmaceutical formulation has a pH from about 6.5 to about 8.5.

11. The liquid pharmaceutical formulation of claim 10, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 1 % (w/w) to about 3.5 % (w/w).

12. The liquid pharmaceutical formulation of claim 10 or 11, wherein the amount of tromethamine or a pharmaceutically acceptable salt thereof in the liquid pharmaceutical formulation is from about 50 mM to about 125 mM.

13. The liquid pharmaceutical formulation of any one of claims 1-9, wherein the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5.

14. The liquid pharmaceutical formulation of any one of claims 1-12, wherein the pH of the liquid pharmaceutical formulation is from about 7 to about 8.

15. The liquid pharmaceutical formulation of claim 1, comprising:
(i) furosemide, or a pharmaceutically acceptable salt thereof;
(ii) from about 1 % (w/w) to about 3.5 % (w/w) benzyl alcohol; and
(iii) from about 50 mM to about 125 mM tromethamine or a pharmaceutically acceptable salt thereof,
wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 80 mg/mL to about 100 mg/mL and the pH of the liquid pharmaceutical formulation is from about 7 to about 8 and is isosmotic.

16. A liquid pharmaceutical formulation, comprising:

(i) furosemide, or a pharmaceutically acceptable salt thereof;

(ii) from about 0.5 % (w/w) to about 5 % (w/w) benzyl alcohol; and

(iii) from about 25 mM to about 250 mM tromethamine or a pharmaceutically acceptable salt thereof,

wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 5 mg/mL to about 100 mg/mL and the pH of the liquid pharmaceutical formulation is from about 5.5 to about 6.5.

17. A unit liquid pharmaceutical formulation comprising:

(i) from about 10 mg to about 200 mg furosemide, or a pharmaceutically acceptable salt thereof;

(ii) from about 0.1 % (w/w) to about 30 % (w/w) of one or more pharmaceutically acceptable excipients selected from the group consisting of ethanol, benzyl alcohol, glycerin, sodium chloride, a polyethylene glycol (PEG), propylene glycol, a polysorbate, a polyvinylpyrrolidone (PVP), and any combination thereof; and

(iii) from about 25 mM to about 250 mM of a pharmaceutically acceptable buffer selected from the group consisting of histidine, a citrate salt, sodium phosphate, potassium phosphate, tromethamine or a pharmaceutically acceptable salt thereof, and any combination thereof,

wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 40 mg/mL to about 250 mg/mL and the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5.

18. The unit liquid pharmaceutical formulation of claim 17, comprising:

(i) from about 60 mg to about 120 mg furosemide, or a pharmaceutically acceptable salt thereof;

(ii) from about 0.5 % (w/w) to about 5 % (w/w) benzyl alcohol; and

(iii) from about 25 mM to about 150 mM tromethamine or a pharmaceutically acceptable salt thereof,

wherein the concentration of furosemide in the unit liquid pharmaceutical formulation is from about 40 mg/mL to about 200 mg/mL and the pH of the liquid pharmaceutical formulation is from about 7 to about 8.

19. The liquid pharmaceutical formulation of any one of claims 1-16, or the unit liquid pharmaceutical formulation of claim 17 or 18, further comprising one of more of water; a pH adjuster; and an osmolarity adjuster.

20. The liquid pharmaceutical formulation or the unit liquid pharmaceutical formulation of claim 19, wherein the pH adjuster is selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and combinations thereof; and the osmolarity adjuster is selected from the group consisting of sodium chloride, potassium chloride, and combinations thereof.

21. A liquid pharmaceutical formulation of any one of claims 1-16, or the unit liquid pharmaceutical formulation of claim 17 or 18, for use in treating congestion, edema, fluid overload, or hypertension in a patient in need thereof.

22. Use of a liquid pharmaceutical formulation of any one of claims 1-16, or the unit liquid pharmaceutical formulation of claim 17 or 18, in the manufacture of a medicament for treating congestion, edema, fluid overload, or hypertension in a patient in need thereof.

23. The liquid pharmaceutical formulation for use, the unit liquid pharmaceutical formulation for use, or use of claim 21 or 22, wherein the liquid pharmaceutical formulation or the unit liquid pharmaceutical formulation is to be administered to the patient by subcutaneous injection or subcutaneous infusion.

24. The liquid pharmaceutical formulation for use, the unit liquid pharmaceutical formulation for use, or use of claim 23, wherein the liquid pharmaceutical formulation is to be administered to the patient by subcutaneous infusion using an on-body, subcutaneous delivery system.

25. The liquid pharmaceutical formulation for use, the unit liquid pharmaceutical formulation for use, or use of claim 24, wherein the on-body, subcutaneous delivery system is a pump device.

26. A kit for the treatment of congestion, edema, fluid overload, or hypertension comprising a liquid pharmaceutical formulation of any one of claims 1-16, or the unit liquid pharmaceutical formulation of claim 17 or 18; and instructions for treating the congestion, edema, fluid overload, or hypertension.